Solutions
Online Inquiry
Inquiry

Chimeric Antigen Receptor (CAR) T Cell Therapy Development

Chimeric antigen receptor (CAR) T cell therapy is a rapidly evolving and promising immunotherapy. This therapy has shown tremendous success in treating certain types of rare diseases. As an innovative company specializing in the development of therapies for rare diseases, our company is dedicated to providing clients with chimeric antigen receptor (CAR) T cell therapy development services.

What is Chimeric Antigen Receptor (CAR) T Cell?

T cells, as an essential component of immune system, play a crucial role in combating external infections and diseases. In recent years, researchers have found that T cells can be artificially transformed into chimeric antigen receptor (CAR) T cells to enhance their anti-cancer efficiency. CAR-T cell involves genetically modifying a patient's own T cells to express a synthetic receptor (the CAR) that targets specific antigens on cancer cells. CAR-T technology has directly altered the way T cells recognize antigens, bypassing MHC restrictions, possessing high specificity, and preventing T cell immune evasion. CAR is designed to express recombinant or chimeric antigen receptors to specific target on cancer cells, by inducing immune response to reduce cancer cell proliferation and cause cell death.

Chimeric antigen receptor (CAR) structure primarily consists of three components:

  • Target receptor segments
  • Membrane-permeable regions
  • Intracellular region

Based on different intracellular regions, CAR-T cells can be divided into first, second, third and fourth generations. Up to now, fourth-generation CAR-T cells perform better in the tumor microenvironment (TME) than previous generations because they possess stronger ability to destroy cancer cells.

Generations of CAR-T cells Fig. 1 Generations of CAR-T cells (Jaromir Tomasik, 2022)

Chimeric Antigen Receptor (CAR) T Cell Therapy

CAR-T cells possess potent ability to target and destroy tumors, and have demonstrated significant anti-tumor activity in various hematologic malignancies such as hemophilia. Diverse structures of CARs enable them potentially feasible for the treatment of multiple rare diseases.

Our Services

Numerous CAR-T cell therapy approaches have been proposed, and these approaches face many challenging issues.

By choosing our company for your CAR-T cell therapy development project, you can take advantage of our proprietary innovations—and deep scientific expertise—which include:

CAR Development CAR Candidate Molecule Development
  • scFv Antibody Library Construction Platform
  • Single Cell Screening Platform
  • Hybridoma Technology Platform
CAR Candidate Molecule Screening
  • scFv Antibody Affinity Assaying
  • Protein Expression Services
  • Cell Line Construction
Deep Sequencing Services
  • Sanger Sequencing
  • NGS Integrated Site Analysis
CAR-T Cells Expansion & Optimizing
  • Lentivirus Production
  • CAR-T Cell Expansion
Animal Studies
  • Transgenic Mouse Model
  • Human Xenograft Mouse Model
  • Off-target Cellular Toxicity Mouse Model

Our Chimeric Antigen Receptor (CAR) T Cell Development Process

Our Chimeric Antigen Receptor (CAR) T Cell Development Process

As a biotechnology company with substantial expertise in chimeric antigen receptor (CAR) T cell therapy development, our company is here to provide our clients with effective, customized treatment approaches through research. If you are interested in our CAR-T cell therapy development services, please contact us for more information.

References

  • Shademan B, Karamad V, Nourazarian A, Avcı CB. CAR T Cells: Cancer Cell Surface Receptors Are the Target for Cancer Therapy. Adv Pharm Bull. 2022;12(3):476-489.
  • Daniel J. Baker, Carl H. June. CAR T therapy extends its reach to autoimmune diseases. Cell, 2022, 185 (24): 4471.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Services

Copyright © Protheragen. All rights reserves.